Imbrium Therapeutics Announces First Patient Dosed in Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation | Small Molecules | News Channels - PipelineReview.com
Submitted by Anonymous (not verified) on Wed, 10/16/2019 - 16:34
